dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
179 |
4. Check minimum number of eventsNone |
179 |
5. Include endpointsNone |
179 |
6. Filter based on genotype QC (FinnGen only) |
172 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Alia dermatomyositis
Similar endpoints
↥List of similar endpoints to
Other dermatomyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 994 | 672 | 312 |
| Only index persons | 759 | 525 | 234 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.13 | 53.64 | 54.89 |
| Only index persons | 51.33 | 51.38 | 51.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 172 | 122 | 50 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 53.66 | 52.73 | 55.91 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 179
- Matched controls
- 1790
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
228.6
167
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
24.5
109.3
109
107
P01BA02
ATC
hydroxychloroquine; oral
19.6
82.9
80
71
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
82.9
73
*
L04AX01
ATC
azathioprine; systemic
34.1
80.2
55
23
L04AX03
ATC
methotrexate; systemic
16.3
75.6
83
90
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
12.0
53.3
67
85
M33.2
ICD-10 Finland
Polymyositis
+∞
42.4
39
*
H02AB06
ATC
prednisolone; systemic
9.3
36.2
148
608
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.9
34.9
124
443
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.2
31.7
40
49
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.0
27.0
42
66
H02AB07
ATC
prednisone; oral
6.3
26.8
57
124
M05BA04
ATC
alendronic acid; oral
7.2
26.3
46
82
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
288.6
25.4
25
*
NXL00
NOMESCO Finland
Biopsy of muscle
275.3
24.3
24
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.9
22.8
31
41
L04AA06
ATC
mycophenolic acid; systemic
45.0
22.4
27
7
ZX120
NOMESCO Finland
Intravenous
6.2
19.4
38
75
L04AD01
ATC
ciclosporin; systemic
28.8
18.8
25
10
L01BA01
ATC
methotrexate; systemic
15.5
17.7
29
22
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.2
17.5
62
200
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
16.9
16
*
M60.9
ICD-10 Finland
Myositis, unspecified
99.5
16.9
18
*
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.8
14
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
14.6
81
347
D07AC01
ATC
betamethasone; topical
3.3
13.8
89
415
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.7
13
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
13.7
13
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
13.0
108
578
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
22.0
12.7
18
9
G72.9
ICD-10 Finland
Myopathy, unspecified
26.6
12.7
17
7
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
12.7
38
106
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
40.6
12.4
15
*
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
29.1
12.3
16
6
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.2
12.1
27
59
D07AB08
ATC
desonide; topical
4.1
12.1
39
115
L04AA01
ATC
[U] ciclosporin
24.9
11.8
16
7
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
69.6
11.8
13
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
11.6
11
*
R4110
NOMESCO Finland
Physiotherapy
3.0
11.2
76
355
M05BA07
ATC
risedronic acid; oral
8.3
10.6
23
31
M60.8
ICD-10 Finland
Other myositis
116.6
10.5
11
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
116.6
10.5
11
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
10.5
10
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
10.3
43
150
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.7
10.3
26
63
XX9XE
NOMESCO Finland
Other ultrasound examination
27.8
10.0
13
5
D07AC13
ATC
mometasone; topical
2.8
9.9
68
317
XQ848
NOMESCO Finland
Dermatological photography
9.5
9.6
19
22
JN4BD
NOMESCO Finland
Extensive body CT
3.7
9.5
33
102
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
9.5
9
*
1XC02, ,
NOMESCO Finland
+∞
9.5
9
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
25.6
9.0
12
5
HA1AA
NOMESCO Finland
X-ray mammography
3.9
8.8
28
81
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
8.7
57
256
R4120
NOMESCO Finland
Occupational therapy
4.2
8.7
25
67
L93.0
ICD-10 Finland
Discoid lupus erythematosus
94.3
8.5
9
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.7
8.2
20
47
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
35.1
8.2
10
*
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
35.1
8.2
10
*
E0000UV, ,
ATC
2.5
8.1
92
537
XG410
NOMESCO Finland
Flow-volume spirometry
8.7
7.8
16
20
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
12.6
7.7
13
11
M05BX04
ATC
denosumab; parenteral
4.6
7.7
19
45
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
83.4
7.5
8
*
Z3226
NOMESCO Finland
Physiotherapist
2.7
7.4
50
227
XPX04
NOMESCO Finland
Angioscopy
+∞
7.3
7
*
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
7.3
67
352
TQW80
NOMESCO Finland
Local dermatologic skincare
9.4
7.2
14
16
Z2221
NOMESCO Finland
Medical doctor
2.4
7.0
66
349
D02AE01
ATC
carbamide; topical
4.4
7.0
18
44
R4190
NOMESCO Finland
Nutritional therapy
7.2
7.0
16
24
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
8.8
7.0
14
17
Z01.8
ICD-10 Finland
Other specified special examinations
2.6
7.0
50
233
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
41.7
6.8
8
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.4
6.8
26
85
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
6.8
49
229
M13.9
ICD-10 Finland
Arthritis, unspecified
3.7
6.5
22
66
R50.9
ICD-10 Finland
Fever, unspecified
2.8
6.4
35
141
L88
ICPC
Rheumatoid/seropositive arthritis
5.8
6.3
17
32
WX892
NOMESCO Finland
Monitored bed care
3.8
6.2
20
58
E000001, ,
ATC
2.5
6.1
47
225
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
6.1
79
474
C03CA01
ATC
furosemide; systemic
2.3
6.0
63
346
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
41
40
13.00
38.36
1.5
1.1
0.20
0.25
g/l
2.41
41
40
41
43
12.07
36.49
1.5
1.1
1.12
1.25
g/l
1.54
41
43
33
38
10.42
27.18
1.9
1.4
—
—
—
0
0
145
807
5.19
19.01
19.9
9.4
4.09
4.06
e9/l
0.06
140
712
18
10
19.82
12.33
1.3
1.0
—
—
—
0
0
18
10
19.82
12.33
1.3
1.0
—
—
—
0
0
18
11
18.02
11.95
1.3
1.0
—
—
—
0
0
18
11
18.02
11.95
1.3
1.0
—
—
—
0
0
18
11
18.02
11.95
1.3
1.0
—
—
—
0
0
20
36
6.13
10.97
1.2
1.4
550.10
0.14
iu/ml
—
6
5
16
10
17.41
10.57
1.1
1.1
—
—
—
0
0
112
673
2.77
9.88
9.8
6.6
1.22
1.22
mmol/l
0.10
101
567
52
227
2.82
8.37
5.4
3.4
0.80
0.81
mmol/l
0.33
47
215
21
52
4.44
8.05
1.3
2.1
—
—
—
0
0
29
95
3.45
7.57
1.2
3.0
64.36
66.66
g/l
0.88
29
87
73
399
2.40
7.26
4.3
2.8
0.17
0.49
e6/l
1.52
57
292
108
704
2.35
7.09
5.5
3.7
0.00
0.00
estimate
-0.00
17
143
106
692
2.30
6.85
5.5
3.7
0.00
0.00
estimate
-0.00
18
155
62
323
2.41
6.79
2.7
2.0
3.83
3.22
mg/l
0.85
57
272
18
34
5.76
6.67
3.9
2.3
—
—
—
0
0
106
697
2.28
6.66
7.7
5.0
0.00
0.00
estimate
-0.00
18
146
94
595
2.22
6.41
3.3
2.2
74.81
77.37
nmol/l
0.43
88
526
82
495
2.21
6.25
4.9
2.8
—
—
—
0
0
41
185
2.58
6.03
2.6
2.0
20.87
22.42
%
0.31
36
163
14
22
6.81
5.99
5.4
2.6
62.36
62.27
%
0.01
14
22
47
232
2.39
5.69
3.4
2.5
0.55
0.83
e6/l
0.78
32
125
16
42
4.09
5.67
1.1
1.1
—
—
—
0
0
34
144
2.68
5.66
9.6
7.3
11.16
12.43
kpa
0.72
28
138
34
144
2.68
5.66
9.6
7.3
5.38
5.03
kpa
0.98
28
138
13
21
6.58
5.50
5.1
2.0
4.29
5.96
e9/l
1.12
13
21
9
10
9.40
4.84
2.2
1.3
—
—
—
0
0
9
10
9.40
4.84
2.2
1.3
—
—
—
0
0
32
145
2.47
4.62
10.1
7.4
1.84
1.14
mmol/l
0.39
25
114
8
8
10.39
4.56
2.6
2.4
—
—
—
0
0
41
210
2.24
4.49
2.3
1.8
—
—
—
0
0
11
21
5.51
4.21
2.1
1.5
—
—
—
0
0
47
261
2.09
4.18
4.5
3.7
223.60
155.61
ng/l
0.26
42
201
11
22
5.25
4.07
1.2
1.4
—
—
—
0
0
41
219
2.13
4.03
3.7
2.7
3.45
2.89
e6/l
0.16
26
114
9
15
6.25
3.86
1.0
1.2
—
—
—
0
0
9
16
5.86
3.71
2.1
1.3
—
—
—
0
0
57
355
1.89
3.62
1.5
1.2
1.05
1.64
u/ml
0.38
12
106
7
9
8.04
3.59
2.7
1.3
—
—
—
0
0
6
6
10.29
3.52
1.0
1.2
94.50
84.15
iu/ml
—
6
6
58
372
1.83
3.32
4.4
3.2
1025.16
1446.74
ng/l
0.66
53
319
31
161
2.12
3.25
2.6
4.5
3.52
77.44
ug/l
0.86
25
133
8
15
5.53
3.23
1.3
1.6
—
—
—
0
0
7
11
6.57
3.21
1.0
1.1
—
—
—
0
0
9
20
4.68
3.16
1.2
1.4
—
—
—
0
0
9
20
4.68
3.16
1.2
1.4
—
—
—
0
0
11
30
3.84
3.14
2.1
1.7
—
—
—
0
0
7
12
6.02
3.05
1.0
1.3
—
—
—
0
0
9
21
4.45
3.04
2.2
1.8
—
—
—
0
0
9
21
4.45
3.04
2.2
1.8
—
—
—
0
0
9
21
4.45
3.04
1.0
1.5
—
—
—
0
0
28
144
2.12
3.01
2.4
1.7
—
—
—
0
0
5
5
10.23
2.99
4.0
1.6
58.60
82.80
ug/l
—
5
5
11
32
3.59
2.95
2.1
1.7
—
—
—
0
0
10
28
3.72
2.83
1.1
1.1
2.20
5.64
u/ml
—
5
11
8
18
4.60
2.83
2.5
1.6
—
—
—
0
0
8
18
4.60
2.83
2.0
1.8
—
—
—
0
0
8
19
4.36
2.71
1.3
1.6
—
—
—
0
0
26
138
2.03
2.58
3.2
2.3
0.20
0.22
g/l
0.76
26
128
9
27
3.45
2.43
1.7
1.7
—
—
—
0
0
40
256
1.72
2.24
1.2
1.2
31.11
42.12
iu/ml
—
9
85
5
9
5.68
2.23
1.4
1.1
—
—
—
0
0
131
1466
0.60
2.21
4.9
4.8
2.90
2.79
mmol/l
0.76
125
1344
73
547
1.56
2.19
5.7
3.7
—
—
—
0
0
8
26
3.17
2.04
2.1
1.7
—
—
—
0
0
7
21
3.42
1.98
1.6
3.0
31.66
86.65
u/ml
—
7
21
125
1402
0.64
1.91
4.3
4.4
5.58
5.92
mmol/l
2.48
120
1281
39
259
1.65
1.90
1.8
1.6
929.84
1277.72
nmol/l
2.19
32
196
7
22
3.27
1.90
1.7
1.5
2.64
174.05
u/ml
—
7
22
7
22
3.27
1.90
3.6
1.2
—
—
—
0
0
130
1440
0.64
1.77
4.5
4.3
4.80
4.73
mmol/l
0.34
124
1324
24
142
1.80
1.75
2.6
1.7
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
5
13
3.92
1.72
1.2
2.3
—
—
—
0
0
50
362
1.53
1.69
3.9
2.6
330.36
8824.32
umol/l
2.48
44
310
8
31
2.65
1.68
2.9
2.0
26.09
25.09
mmol/l
—
8
31
8
31
2.65
1.68
1.1
1.0
—
—
—
0
0
6
19
3.23
1.67
1.5
1.5
—
—
—
0
0
32
209
1.65
1.66
2.5
1.7
33.61
29.54
s
0.90
32
203
8
33
2.49
1.55
2.1
1.3
—
—
—
0
0
130
1430
0.67
1.54
4.5
4.3
1.47
1.52
mmol/l
0.76
124
1308
5
15
3.40
1.53
1.2
2.0
—
—
—
0
0
12
58
2.15
1.53
1.1
1.4
—
—
—
0
0
12
58
2.15
1.53
4.8
3.4
39.09
45.82
%
0.40
12
58
80
648
1.42
1.51
16.7
11.9
1.34
1.21
inr
0.47
23
185
11
52
2.19
1.47
1.4
1.3
—
—
—
0
0
10
46
2.24
1.42
2.0
1.8
—
—
—
0
0
5
17
2.99
1.37
1.2
1.9
—
—
—
0
0
12
61
2.04
1.36
2.2
2.5
45.83
42.67
u/l
0.27
12
55
26
171
1.61
1.32
13.4
6.4
103.88
104.12
mmol/l
0.10
26
171
43
317
1.47
1.32
1.7
1.7
1.29
1.14
mg/l
0.19
31
250
51
390
1.43
1.30
6.7
3.8
0.00
0.00
estimate
-0.00
17
145
35
249
1.50
1.28
1.2
1.2
8.83
19.68
u/ml
—
9
89
16
93
1.79
1.26
1.4
1.6
—
—
—
0
0
8
37
2.22
1.23
1.1
1.1
—
16.98
—
0
6
126
1375
0.72
1.18
4.0
3.9
1.32
1.27
mmol/l
0.41
121
1248
37
273
1.45
1.13
1.5
1.5
—
—
—
0
0
5
21
2.42
1.10
1.6
1.1
—
—
—
0
0
10
52
1.98
1.08
2.3
2.1
—
—
—
0
0
7
35
2.04
1.01
4.3
2.7
54.29
36.33
u/ml
—
7
35
80
684
1.31
0.97
3.4
2.5
—
—
—
0
0
11
63
1.79
0.92
1.8
1.3
—
—
—
0
0
13
79
1.70
0.91
1.2
1.6
—
—
—
0
0
15
225
0.64
0.89
3.0
4.5
22.44
21.63
%
—
8
113
13
80
1.67
0.87
1.0
1.0
—
—
—
0
0
8
140
0.55
0.87
1.4
1.6
—
—
—
0
0
0
24
0.00
0.80
0.0
1.3
—
—
—
0
0
106
960
1.26
0.75
3.6
2.9
53.24
45.72
u/l
0.47
101
906
155
1475
1.38
0.72
29.9
12.7
20.97
22.79
mg/l
0.31
138
1142
157
1624
0.73
0.62
42.8
19.6
39.59
39.96
%
0.36
143
1527
8
51
1.59
0.61
1.3
1.6
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
61
531
1.23
0.60
3.5
3.6
131.08
29.74
ng/l
0.97
50
353
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
6
35
1.74
0.58
1.0
1.7
—
—
—
0
0
12
83
1.48
0.53
14.8
5.7
26.79
25.04
mmol/l
0.67
12
83
10
67
1.52
0.51
3.1
2.3
0.65
0.68
%
—
10
67
18
137
1.35
0.49
6.4
3.8
—
—
—
0
0
13
176
0.72
0.49
10.9
6.6
—
—
—
0
0
10
69
1.48
0.45
3.1
2.3
1.25
1.09
%
—
10
69
10
69
1.48
0.45
2.6
3.5
2.03
1.16
mmol/l
—
10
51
127
1332
0.84
0.45
6.0
5.5
40.40
39.55
mmol/mol
0.47
122
1233
0
15
0.00
0.41
0.0
2.0
—
2.20
—
0
5
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
5
34
1.48
0.40
4.2
1.7
—
—
—
0
0
63
569
1.17
0.40
2.3
1.9
92.90
96.78
pmol/l
0.34
34
279
0
18
0.00
0.40
0.0
1.8
—
10.72
—
0
6
5
35
1.44
0.39
1.0
1.6
—
—
—
0
0
87
934
0.87
0.39
3.2
3.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
13
169
0.75
0.39
2.4
2.8
0.72
0.75
ug/l
—
8
111
7
52
1.36
0.31
1.3
1.1
—
—
—
0
0
39
347
1.16
0.30
2.2
2.4
—
—
—
0
0
133
1375
0.87
0.30
24.1
12.7
88.76
82.12
ml/min/173m2
2.16
120
1112
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
41.00
—
0
7
0
12
0.00
0.21
0.0
1.0
—
452.71
—
0
7
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
51
1.18
0.19
1.2
1.1
—
—
—
0
0
7
62
1.13
0.17
1.6
1.7
—
—
—
0
0
109
1121
0.93
0.15
5.5
4.1
14.85
14.71
pmol/l
0.25
101
1011
26
284
0.90
0.14
3.3
5.0
2.35
1.99
ug/l
0.16
21
252
14
122
1.16
0.14
3.4
2.1
88.60
66.08
ml/min/173m2
—
5
50
13
149
0.86
0.14
2.2
1.8
—
—
—
0
0
38
399
0.94
0.09
1.7
1.6
1.45
1.36
mmol/l
0.23
32
331
6
55
1.09
0.09
1.0
1.5
—
—
—
0
0
29
273
1.07
0.09
1.4
1.4
—
—
—
0
0
156
1544
1.08
0.08
32.4
15.5
71.54
74.08
umol/l
0.30
156
1544
9
85
1.06
0.07
1.6
1.8
—
—
—
0
0
11
106
1.04
0.00
1.5
1.3
60.34
139.70
iu/ml
—
5
42
40
404
0.99
0.00
3.3
3.7
3.05
9.76
mg/mmol
1.85
20
243
134
1343
0.99
0.00
5.9
4.9
1.77
1.90
mu/l
0.63
125
1218
17
168
1.01
0.00
2.1
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
9
92
0.98
-0.00
1.2
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
204.07
—
0
9
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
17.20
—
0
5
0
8
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOMYOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 2.82 [2.11, 3.76] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.762 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 411 females with M13_DERMATOMYOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 3.103 [2.28, 4.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 201 males with M13_DERMATOMYOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOMYOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.228% | 0.515% |
| 5 | 1.755% | 3.094% |
| 10 | 4.592% | 7.916% |
| 15 | 9.262% | 14.67% |
| 20 | 16.456% | 24.478% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOMYOTH – Other dermatomyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data